

ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe

Concluding Remarks

Nathan I Cherny

Norman Levan Chair in Humanistic Medicine

Dept Oncology

Unit Head: Cancer pain and palliative Medicine

Shaare Zedek Medical Center

Chernyn@Netvision.net.il

Preliminary Conclusions


- There are substantial differences in formulary availability , out of pocket costs and actual availability for many medications
- These differences
 - Are more profound in Eastern European Countries
 - Are related to the cost of new agents
- The impact of these differences are most profound in diseases where non curative outcomes are dependent on availability of expensive anticancer agents such as
 - EGFR or ALK mutated non small cell lung cancer
 - Melanoma
 - Renal Cell Cancer
 - RAS/RAF wild type colorectal cancer

\$1000 per tablet



Make important medicines cheaper

International New York Times | <http://nyti.ms/1qDD7C3>



INTERNATIONAL BUSINESS | NYT NOW

Maker of Costly Hepatitis C Drug Sovaldi Strikes Deal on Generics for Poor Countries

By GARDINER HARRIS SEPT. 15, 2014

NEW DELHI — The maker of one of the costliest drugs in the world announced on Monday that it had struck deals with seven generic drug makers in India to sell lower-cost versions of the medicine — a \$1,000-a-pill hepatitis C treatment — in poorer countries.

Gilead Sciences, which is based in California, also said it would begin selling its own version of the drug in India and other developing countries at a fraction of the price it charges in the United States.


The company intends to provide greater access to the medicine, Sovaldi, for most of the nearly 180 million infected worldwide with hepatitis C who do not live in rich countries. Some 350,000 people die every year of hepatitis C infections, most of them in middle- and low-income nations.

Sovaldi, in only its initial year on the market after gaining approval in the United States in December, is on pace to exceed \$10 billion in sales in 2014, becoming one of the world's best-selling drugs. Its high price has led to intense criticism even in the United States, where officials say it could drain Medicaid budgets and insurers say it could cause increases in

Finding the right balance for the cancer medicine industry



Finding the right balance for the cancer medicine industry



Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing

Bruce E. Hillner and Thomas J. Smith, *Department of Internal Medicine and the Massey Cancer Center, Virginia Commonwealth University, Richmond, VA*

(Table 1). Profiteering, the act of making a profit by methods considered unethical, such as raising prices after a natural disaster, is a pejorative term that we believe can be applied to this recent trend where a life-threatening disease is the natural disaster. Inequalities of

Professional public health advocacy

■ Responsibility

- Individual clinicians
- Professional organizations

■ Advocate for

- Affordability
 - Pharmaceutical industry: reduce prices
 - Governments: subsidies and reimbursements
- Equal access to care

■ Pharmaceutical industry

- Not bound by same ethical commitments as physicians
- Inherently seek to maximize profit and return
- Dynamic relationship: sometimes partner, sometimes adversary